U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT07574294) titled 'Dual REmission in Moderate-to-SEvere asthMa and Nasal Polyps' on April 28.
Brief Summary: Background: "Remission" is a primary therapeutic goal in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), though definitions vary regarding olfactory function. We evaluated "Dual Remission" kinetics in patients treated with dupilumab over 24 months. Methods: This single-center retrospective study analyzed 28 patients with comorbid severe asthma and CRSwNP. Dual Remission was defined as simultaneous asthma remission (Asthma Control Test (ACT) >= 20, no exacerbations, no oral corticosteroids (OCS) and stable lung function) and C...